Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study

Launched by UCB PHARMA · Jan 22, 2008

Keywords

ClinConnect Summary

This is a non-interventional, prospective, post-authorization, multi-centre cohort study in patients treated with levocetirizine.

The baseline data will be collected at the visit to the physician when levocetirizine is prescribed for the first time for the patient for Persistent Allergic Rhinitis. The data will then be collected during 2 visits occurring within the first 6 months of treatment, as usually scheduled in normal clinical practice in the Czech and Slovak Republics. This is after approximately 4 weeks and 6 months of treatment or earlier, if the treatment is stopped

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of persistent allergic rhinitis
• • first prescription of levocetirizine for this diagnosis for this patient
• • age ≥ 2 years
• Exclusion Criteria:
• • indications other than those defined in inclusion criteria
• • history of allergic or anaphylactic reactions to levocetirizine or other derivatives and excipients included